The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How can we tackle immune evasion in Hodgkin lymphoma?

Dec 16, 2019

During the 61 stAmerican Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub was pleased to speak to Ann Lacasce, Dana-Farber Cancer Institute, Boston, US. We asked: How can we tackle immune evasion in Hodgkin lymphoma?

Ann Lacasce discusses new immunotherapies in lymphoma. She talks about the results of clinical trials that assess the efficacy of checkpoint inhibitors and CAR T therapy. She explains that she anticipates the results will potentially be tolerable and durable

How can we tackle immune evasion in Hodgkin lymphoma?